litlas
Log inCreate account

Heidi A. Lane

Active 1989–2024

47
Papers
19,623
Citations
42
h-index
46
i10-index

Citations

Citations per year for Heidi A. Lane1990: 3 citations1991: 7 citations1992: 5 citations1993: 1 citations1994: 17 citations1995: 16 citations1996: 24 citations1997: 33 citations1998: 83 citations1999: 50 citations2000: 76 citations2001: 104 citations2002: 126 citations2003: 149 citations2004: 146 citations2005: 216 citations2006: 253 citations2007: 263 citations2008: 353 citations2009: 366 citations2010: 388 citations2011: 357 citations2012: 282 citations2013: 295 citations2014: 268 citations2015: 186 citations2016: 158 citations2017: 143 citations2018: 124 citations2019: 398 citations2020: 392 citations2021: 366 citations2022: 265 citations2023: 195 citations2024: 273 citations2025: 126 citations2026: 4 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,817 citing papers, 34.7% of this breakdownChina: 696 citing papers, 8.6% of this breakdownUnited Kingdom: 504 citing papers, 6.2% of this breakdownGermany: 426 citing papers, 5.3% of this breakdownItaly: 368 citing papers, 4.5% of this breakdownSwitzerland: 300 citing papers, 3.7% of this breakdownFrance: 294 citing papers, 3.6% of this breakdownJapan: 283 citing papers, 3.5% of this breakdownCanada: 262 citing papers, 3.2% of this breakdownSpain: 248 citing papers, 3.1% of this breakdownNetherlands: 149 citing papers, 1.8% of this breakdownAustralia: 148 citing papers, 1.8% of this breakdown
0%34.7%Other 20%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology49.6%
  • Medicine42.8%
  • Immunology and Microbiology1.9%
  • Chemistry1.4%
  • Neuroscience1.2%
  • Computer Science0.9%
  • Other2.2%

Topics

  • PI3K/AKT/mTOR signaling in cancer7.8%
  • HER2/EGFR in Cancer Research6.2%
  • Microtubule and mitosis dynamics4%
  • Monoclonal and Polyclonal Antibodies Research3.3%
  • Cancer-related Molecular Pathways2.6%
  • Lung Cancer Treatments and Mutations2.6%
  • Other73.5%

Coauthors

All papers

Open in search
  1. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells

    Authors: Don Benjamin, Dimitri Robay, Sravanth K. Hindupur, Jens Pohlmann, Marco Colombi, Mahmoud El‐Shemerly, Sauveur-Michel Maira, Christoph Moroni, Heidi A. Lane, Michael N. Hall - Cell Reports 2018 cited by 382

  2. ERBB receptors and cancer: the complexity of targeted inhibitors

    Authors: Nancy E. Hynes, Heidi A. Lane - Nature reviews. Cancer 2005 cited by 3,310

  3. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

    Authors: Kathryn O’Reilly, F. Rojo, Qing‐Bai She, David B. Solit, Gordon B. Mills, Debra L. Smith, Heidi A. Lane, Francesco Hofmann, Daniel J. Hicklin, Dale L. Ludwig, José Baselga, Neal Rosen - Cancer Research 2006 cited by 2,552

  4. The ErbB signaling network: receptor heterodimerization in development and cancer

    Authors: Monilola A. Olayioye, Richard M. Neve, Heidi A. Lane, Nancy E. Hynes - The EMBO Journal 2000 cited by 2,439

  5. Syrosingopine sensitizes cancer cells to killing by metformin

    Authors: Don Benjamin, Marco Colombi, Sravanth K. Hindupur, Charles Betz, Heidi A. Lane, Mahmoud El‐Shemerly, Min Lu, Luca Quagliata, Luigi Terracciano, Suzette Moes, Timothy Sharpe, Aleksandra Wodnar‐Filipowicz, Christoph Moroni, Michael N. Hall - Science Advances 2016 cited by 81

  6. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

    Authors: Pradip K. Majumder, Phillip G. Febbo, Rachel Bikoff, Raanan Berger, Qi Xue, Louis McMahon, Judith Manola, James Brugarolas, Timothy J. McDonnell, Todd R. Golub, Massimo Loda, Heidi A. Lane, William R. Sellers - Nature Medicine 2004 cited by 956

  7. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo

    Authors: Anne Blangy, Heidi A. Lane, Pierre d'Hérin, Maryannick Harper, Michel Kress, Erich A. Nigg - Cell 1995 cited by 971

  8. Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function

    Authors: Lynsey M. Meikle, Kristen Pollizzi, Anna Egnor, Ioannis Kramvis, Heidi A. Lane, Mustafa Şahin, David J. Kwiatkowski - Journal of Neuroscience 2008 cited by 503

  9. Detection of circulating tumour cell clusters in human glioblastoma

    Authors: Ilona Krol, Francesc Castro-Giner, Martina Maurer, Sofia Gkountela, Barbara M. Szczerba, Ramona Scherrer, Niamh Coleman, Suzanne Carreira, Felix Bachmann, Stephanie Anderson, Marc Engelhardt, Heidi A. Lane, T.R. Jeffry Evans, Ruth Plummer, Rebecca Kristeleit, Juanita Lopez, Nicola Aceto - British Journal of Cancer 2018 cited by 144

  10. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.

    Authors: Heidi A. Lane, Erich A. Nigg - The Journal of Cell Biology 1996 cited by 690

  11. The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization

    Authors: A.E. Prota, Franck Danel, Felix Bachmann, Katja Bargsten, Rubén M. Buey, Jens Pohlmann, Stefan Reinelt, Heidi A. Lane, Michel O. Steinmetz - Journal of Molecular Biology 2014 cited by 307

  12. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

    Authors: José Baselga, Semiglazov Vf, Peter van Dam, Alexey Manikhas, Meritxell Bellet, José Mayordomo, Mario Campone, E. Kubista, Richard Greil, Giulia Bianchi, Jutta Steinseifer, Betty Molloy, Erika Tokaji, Humphrey Gardner, Penny Phillips, Michael Stumm, Heidi A. Lane, J. Michael Dixon, W. Jonat, Hope S. Rugo - Journal of Clinical Oncology 2009 cited by 658

  13. AEE788

    Authors: Peter Traxler, Peter R. Allegrini, Ralf Brandt, Josef Brueggen, Robert Cozens, Doriano Fabbro, Konstantina Grosios, Heidi A. Lane, Paul M.J. McSheehy, Jürgen Mestan, Thomas Meyer, Careen K. Tang, Markus Wartmann, Jeanette M. Wood, Giorgio Caravatti - Cancer Research 2004 cited by 318

  14. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

    Authors: Madlaina Breuleux, Matthieu Klopfenstein, Christine Stephan, Cheryl A. Doughty, Louise Barys, Saveur-Michel Maira, David J. Kwiatkowski, Heidi A. Lane - Molecular Cancer Therapeutics 2009 cited by 241

  15. The role of overexpressed HER2 in transformation

    Authors: Richard M. Neve, Heidi A. Lane, Nancy E. Hynes - Annals of Oncology 2001 cited by 173

  16. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

    Authors: Saskia M. Brachmann, Irmgard Hofmann, Christian Schnell, Christine Fritsch, Susan Wee, Heidi A. Lane, Shaowen Wang, Carlos Garcı́a-Echeverrı́a, Sauveur-Michel Maira - National Academy of Sciences, Proceedings of the National Academy of Sciences 2009 cited by 319

  17. The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation

    Authors: Iwan Beuvink, Anne Boulay, Stefano Fumagalli, Frédéric Zilbermann, Stephan Ruetz, Terence O’Reilly, François Natt, Jonathan Hall, Heidi A. Lane, George Thomas - Cell 2005 cited by 490

  18. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

    Authors: Anne O’Donnell, Sandrine Faivre, Howard A. Burris, Daniel Rea, Vassiliki A. Papadimitrakopoulou, Nicholas Shand, Heidi A. Lane, Katharine Hazell, Ulrike Zoellner, John M. Kovarik, Cathryn Brock, Suzanne F. Jones, Éric Raymond, Ian Judson - Journal of Clinical Oncology 2008 cited by 479

  19. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts

    Authors: Michaela Kneissel, Ngoc-Hong Luong-Nguyen, Myma Baptist, Reto Cortesi, Sabine Zumstein-Mecker, Σοφία Κοσσίδα, Terry O’Reilly, Heidi A. Lane, Mira Šuša - Bone 2004 cited by 161

  20. Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells

    Authors: Anne Boulay, Sabine Zumstein-Mecker, Christine Stephan, Iwan Beuvink, Frédéric Zilbermann, Roland Haller, Sonja Tobler, Christoph Heusser, Terence O’Reilly, Barbara Stolz, Andreas Marti, George Thomas, Heidi A. Lane - Cancer Research 2004 cited by 319

  21. mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

    Authors: Heidi A. Lane, Jeanette M. Wood, Paul M.J. McSheehy, Peter R. Allegrini, Anne Boulay, Joseph Brueggen, Amanda Littlewood‐Evans, Sauveur-Michel Maira, Georg Martiny‐Baron, Christian Schnell, Patrizia Sini, Terence O’Reilly - Clinical Cancer Research 2009 cited by 251

  22. Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules

    Authors: Danielle M. Burgenske, Surabhi Talele, Jenny L. Pokorny, Ann C. Mladek, Katrina K. Bakken, Brett L. Carlson, Mark A. Schroeder, Lihong He, Zeng Hu, Gautham Gampa, Matthew Kosel, Paul A. Decker, Gaspar J. Kitange, Anne Schmitt‐Hoffmann, Felix Bachmann, Rachael A. Vaubel, Jeanette E. Eckel‐Passow, Caterina Giannini, Paul M.J. McSheehy, Heidi A. Lane, William F. Elmquist, Jann N. Sarkaria - Neuro-Oncology 2021 cited by 18

  23. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)

    Authors: Vassilis Genoud, Felipe I. Espinoza, Eliana Marinari, Viviane Rochemont, Pierre‐Yves Dietrich, Paul M.J. McSheehy, Felix Bachmann, Heidi A. Lane, Paul R. Walker - JCI Insight 2021 cited by 15

  24. Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

    Authors: Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard A. Burris, Ian Judson, Katharine Hazell, Erika Martinelli, Santiago Ramón y Cajal, Suzanne F. Jones, Laura Vidal, Nicholas Shand, Teresa Macarulla, Francisco Javier Ramos, Saša Dimitrijević, Ulrike Zoellner, Pui Tang, Michael Stumm, Heidi A. Lane, David Lebwohl, José Baselga - Journal of Clinical Oncology 2008 cited by 532